Dr Myra Hardy is a Paediatric Infectious Diseases Physician with a strong interest in global health that stems from her early research evaluating the burden of rheumatic heart disease in school children in Tonga. During her paediatric training, she has worked in Melbourne, Darwin, Solomon Islands and Canada. She has recently completed her PhD based in Fiji investigating the safety and efficacy of Ivermectin, Diethylcarbamazine, and Albendazole for lymphatic filariasis control and the non-inferiority of one-dose versus two-dose Ivermectin-based Mass drug administration (MDA) for the community control of scabies.

Myra is currently a postdoctoral researcher in the Tropical Diseases group, Infection, Immunity and Global Health research area at Murdoch Children’s Research Institute. Her ongoing research focuses on the acceptability of ivermectin, diethylcarbamazine and albendazole, the impact on soil-transmitted helminths and further evaluation of the efficacy of treatments for lymphatic filariasis in Fiji.